Biotech Values

[genisi]

I certainly agree with your view that exaggerating Section 271(e)(1) beyond the intent of the law would make the value of patents like Momenta's worth a lot less (using iwfal's words #msg-67816773). Still, from previous cases where utilizing patented techniques was allowed so long as it was related to gaining data for FDA approval for an ANDA, seems to me it is within the scope of Section 271(e)(1). Btw, Momenta will probably use the Bolar Provision in the Copaxone case (#msg-59195596).